Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Hemant Thukral of Aditya Birla Money is of the view that one can go long in Strides Arcolab for a target of Rs 1350-1375.
CK Narayan, MD, Growth Avenues Asset Advisors is of the view that one may pick Mindtree, Strides Arcolab and Aurobindo Pharma.
Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.
Hemant Thukral of Aditya Birla Money is of the view that one can pick Aurobindo Pharma from the pharma space with a target of Rs 770-780.
According to Gautam Trivedi, MD & CEO of Religare Capital Markets, Strides Arcolab is a top pick in the midcap pharma space.
Gaurav Bissa of LKP Securities suggests buying Bank of Baroda with a target of Rs 200.
Kunal Bothra of LKP Securities recommends buying Strides Arcolab and Tech Mahindra.
Dipan Mehta, Member of BSE & NSE is positive on Strides Arcolab.
According to Hemant Thukral of Aditya Birla Money, Wockhardt is a good traders pick and feels that it may test Rs 1550.
Deepak Shenoy of Capitalmind.in is of the view that one may go long in Sun Pharma and Strides Arcolab and likes midcap IT space including Sterlite Technologies.
Sharmila Joshi, Market Expert is of the view that one may buy Shriram Transport with a target of Rs 880.
Hemen Kapadia of KRChoksey Securities is of the view that one may buy Kotak Mahindra Bank with a target of Rs 640.
Gaurav Ratnaparkhi of Sharekhan is of the view that one may sell Strides Arcolab with a target of Rs 1088.
Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.
Kunal Bothra of LKP Securities is of the view that one can buy Strides Arcolab and Divis Laboratories on dips.
Rahul Mohindar of viratechindia.com is of the view that Infosys can rise by 5-8 percent.
Kunal Saraogi of Equityrush recommends buying Strides Arcolab and advises selling Tata Motors.
Jay Thakkar of ShareKhan suggests selling Axis Bank with a target of Rs 490.
Sudarshan Sukhani of s2analytics.com recommends selling Indiabulls Real Estate and Power Finance Corporation and advises buying Strides Arcolab.
Rakesh Bansal of RK Global advises buying Bank of Baroda with a target of Rs 197.
Rahul Mohindar of viratechindia.com is of the view that Strides Arcolab should move to Rs 1360.
Sudarshan Sukhani of s2analytics.com advises buying Strides Arcolab and BPCL.
Avinnash Gorakssakar of Precision Investment Services advises buying Jubilant Foodworks with a target of Rs 1930.
Ashish Chaturmohta of Fortune Group recommends buying ICICI Bank, Strides Arcolab and BHEL.
Manas Jaiswal of manasjaiswal.com recommends buying Kotak Mahindra Bank and Strides Arcolab.